Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
GlobalData on MSN8d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
My goal upon joining Mount Gilead was to leave a positive impact on the school district and make it even better than it was ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback